MGB-backed biotech raises $85m to develop drugs for diseases that cause scarring in organs

A small Cambridge biotech said Wednesday it has raised $85 million in fresh venture capital and appointed a pharmaceutical industry veteran chief executive as the startup works on potential treatments for fibrosis, the often deadly scarring of organs caused by a variety diseases.

Access the article on (paywall)